Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma.
Ontology highlight
ABSTRACT: HER-3 expression has been reported to act as an important oncoprotein in head and neck squamous cell carcinoma. This protein is known to control tumor proliferation and acquisition of resistance by tumor cells towards EGFR inhibitors, therefore, development of a HER-3-targeted therapy is desirable. In this study, we found that HER-3 expression on tumor cells was increased after EGFR inhibition. To establish a novel therapeutic approach for HER-3-positive head and neck carcinoma, we identified a HER-3 helper epitope that could elicit effective helper T cell responses to the naturally processed HER-3-derived epitope presented in a HER-3 expressing tumors. This epitope induced potent cytolytic activity of CD4 T cells against such tumor cells. Moreover, pan HER-family tyrosine kinase inhibitor
SUBMITTER: Kumai T
PROVIDER: S-EPMC4633732 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA